目前全国部分医学院校与当地综合大学进行合并调整后,不少作者在投稿时,对所在单位的中、英文名称的书写不够规范,不少单位在开具推荐信（即介绍信）时,使用的公章与文稿中所书写的不一致。单位名称书写不规范,将影响读者与作者之间的联系及文稿发表后文献计量学的统计等工作。为此,本刊就作者单位名称的书写要求如下:（1）作者在投稿时,首先应列出单位名称的全称,如已归属于综合大学的单位,应先列出大学名
1.数值范围号的使用应统一,一般使用浪纹连接号" ～ " . 例如:5 至10 可写成5 ～10;但5 万至10 万应写成5 万～10 万. 2.幂次相同的参数范围:前一个参数的幂次不能省略. 例如3 ×109 ～5 ×109 不能写成3 ～5 ×109,但可以写成(3 ～5) ×109. 3.百分数范围:前一个参数的百分号不能省略. 例如:20％ ～30％不能写成20 ～30％.
Objective:By observing the clinical characteristics of patients with diabetic kidney disease(DKD)with subclin-ical hypothyroidism(SCH),the clinical characteristics and distribution differences of TCM syndrome of DKD patients with SCH are discussed and analyzed,which provides certain value to the syndrome differentiation treatment of such patients.Methods:Through retrospective analysis,484 DKD patients were hospitalized in the Department of Nephrology and Endocrinology of Dongzhimen Hospital of Beijing University of Chinese Medicine for recent 5 years,among which 186 patients with SCH were in the DKD +SCH group(The 49 cases where TSH≥10.0 mIu/L was severe and 137 cases were 4.0 mIu/L TSH 10 mIu/L was mild),A total of 298 DKD patients without SCH were included in the DKD alone group and 246 patients in the type 2 diabetes group.The differences in gender,age,disease duration,thyroid function index and antibody level,renal function,HbA1c,24 h urinary protein quantification,and blood lipid were compared,and the proportion and distribution characteristics of TCM syndrome in DKD + SCH group were analyzed,and the relevant risk factors of different TCM syndrome were explored.Results:The levels of Scr,BUN,24 Upr,HbA1c,LDL-C,com-bined DL-C,TC,TC,TG,and HDL-C were all higher than patients with DKD alone or type 2 diabetes,with a statistically signifi-cant difference(P<0.05);The DKD patients with SCH had mostly lower spleen and kidney Yang deficiency syndrome,and the sig-nificantly lower FT4 level and significantly higher TSH level were observed,with a statistically significant difference(P<0.05);Risk factor analysis of DKD patients complicated with SCH found that sex,BMI,SBP,TSH,FT4,and Scr were independent risk fac-tors for progression to spleen and kidney Yang deficiency(P<0.05).Conclusion:DKD patients have different degrees of thyroid dysfunction;The renal function,blood lipid and saccharification indexes of SCH patients are different compared with simple DKD pa-tients or type 2 diabetes patients.Their TCM syndrome is mainly spleen and kidney Yang deficiency syndrome,and their thyroid func-tion is different among different TCM syndrome types,and the spleen and kidney Yang deficiency syndrome,qi stagnation and blood stasis syndrome are closely related to the progression of disease and SCH formation in DKD patients;In clinical practice,it is necessa-ry to correctly manage lifestyle,pay attention to timely changes of thyroid function,and adopt symptomatic treatment of spleen invigor-ating kidney and promoting blood circulation and removing blood stasis as soon as possible,which can provide important reference val-ue for delaying the progression of DKD and preventing the occurrence and development of hypothyroidism.
Objective:To systematically evaluate the clinical effect and safety of Shenkang Injection with Alprostadil(exper-imental group)versus Alprostadil alone(control group)on chronic renal failure(CRF),and to provide reference for clinical use.Methods:RevMan 5.4 provided by the Cochran collaboration was applied to risk assessment and meta-analysis of the included RCTs.Results:A total of 9 studies involving 691 patients were included.Meta analysis indicated that the experimental group had ad-vantages in total clinical effective rate(RR =1.24,95%CI[1.16,1.33],P<0.000 01),BUN(MD =-4.28,95%CI[-6.10,-2.46],P<0.000 01),Scr(MD =-51.91,95%CI[-68.11,-35.70],P<0.000 01),Ccr(MD = 5.78,95%CI[2.15,9.41],P =0.002),24 h Upro(MD =-0.56,95%CI[-0.66,-0.46],P<0.000 01)compared with the control group.But there were no significant difference in incidence of adverse reactions between two groups.Serious adverse reactions were not found.Conclu-sion:Compared with Alprostadil alone,Shenkang Injection with Alprostadil has better efficiancy,and deserved to be promoted for clinical use.However,due to the low quality of evidence,more rigorous,multicenter,randomized double-blind,large sample ran-domized controlled trials are needed for further exploration.
慢性肾脏病(CKD)因其高患病率、高致残率、高医疗花费和低知晓率——"三高一低"的特征,已成为全球范围内危害人类健康的重要公共卫生问题[1] .全球疾病负担研究显示,2017 年全球CKD患病率为9.1％,CKD 1 ～ 2 期为 5.
